Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)

Completed · Phase 4

Conditions studied: Kidney Diseases

In brief

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.

Key facts

Study ID

NCT00289614

Run by

Bracco Diagnostics, Inc

People needed

350

Starts

2006-01-01

Expected to finish

2007-04-01

Last updated by the study team

2008-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Referred for contrast enhanced MDCT
• Documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2
• Diagnosed as having diabetes mellitus

You may not qualify if…

• Unstable renal function
• Unstable diabetes
• Concurrent administration of nephrotoxic drugs
• Undergoing dialysis

Where it is running

• Bracco Diagnostics, Inc. — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.